These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3110997)

  • 21. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
    van Giezen JJ; Boon GI; Jansen JW; Bouma BN
    Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Analysis of plasminogen activator in human plasma using the method of fibrin/celite column chromatography--with special reference to the determination of fibrin adsorbable tissue-plasminogen activator by ELISA].
    Ieko M
    Hokkaido Igaku Zasshi; 1985 Nov; 60(6):834-47. PubMed ID: 4085966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of monoclonal antibodies to human tissue-type plasminogen activator: catalytic inhibition and one-two chain discriminatory reactivities.
    Stigbrand T; Frängsmyr L; Bergsdorf N; Wallen P
    Thromb Haemost; 1989 Sep; 62(2):742-7. PubMed ID: 2479112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH; Rijken DC
    Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium.
    Stegnar M; Zore A; Novak-Antolic Z; Vovk N; Kruithof EK
    Thromb Haemost; 1993 Sep; 70(3):486-90. PubMed ID: 8259554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An enhancing effect of poly-lysine on the activation of plasminogen.
    Allen RA
    Thromb Haemost; 1982 Feb; 47(1):41-5. PubMed ID: 7200268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diurnal variation of the fibrinolytic system.
    Grimaudo V; Hauert J; Bachmann F; Kruithof EK
    Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An enzyme linked immunosorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic disease.
    Bergsdorf N; Nilsson T; Wallén P
    Thromb Haemost; 1983 Oct; 50(3):740-4. PubMed ID: 6359572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A sensitive bioimmunoassay for thrombin-cleaved two-chain urokinase-type plasminogen activator in human body fluids.
    Braat EA; Nauland U; Dooijewaard G; Rijken DC
    Thromb Haemost; 1996 Jun; 75(6):908-14. PubMed ID: 8822585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
    Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
    Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Actin stimulates plasmin generation by tissue and urokinase-type plasminogen activators.
    Lind SE; Smith CJ
    Arch Biochem Biophys; 1993 Nov; 307(1):138-45. PubMed ID: 8239651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
    Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
    Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasminogen activator inhibitor-1 is the primary inhibitor of tissue-type plasminogen activator in pregnancy plasma.
    Jørgensen M; Philips M; Thorsen S; Selmer J; Zeuthen J
    Thromb Haemost; 1987 Oct; 58(3):872-8. PubMed ID: 3124286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A dynamic test to investigate potential tissue plasminogen activator activity. Comparison of deamino-8-D-argininevasopressin with venous occlusion in normal subjects and patients.
    Sultan Y; Harris A; Strauch G; Venot A; De Lauture D
    J Lab Clin Med; 1988 Jun; 111(6):645-53. PubMed ID: 3131470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Functional characterization of a monoclonal antibody which interferes with the binding of t-PA to fibrin].
    Orbe J; Montes R; Chordá C; Páramo JA; Rocha E
    Sangre (Barc); 1994 Aug; 39(4):261-6. PubMed ID: 7985055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibrin-specific thrombolytic agents.
    Collen D
    Klin Wochenschr; 1988; 66 Suppl 12():15-23. PubMed ID: 3126344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tissue-type plasminogen activator concentrations in plasma from patients with psoriasis.
    Grøndahl-Hansen J; Ottevanger V
    Acta Derm Venereol; 1989; 69(5):391-4. PubMed ID: 2572102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay.
    Rijken DC; Juhan-Vague I; de Cock F; Collen D
    J Lab Clin Med; 1983 Feb; 101(2):274-84. PubMed ID: 6681623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.